Boston Scientific's (BSX) Settlement with J&J (JNJ) is Credit-Negative Event - Moody's

Moody's Investors Service said that Boston Scientific Corporation's (NYSE: BSX) announced $600 million settlement with Johnson & Johnson (NYSE: JNJ) -- related to a longstanding lawsuit alleging breach of contract over the 2006 acquisition of Guidant Corporation -- is credit negative but does not have an effect on Boston's Baa3 ratings or stable outlook at this time.

You May Also Be Interested In

• Boston Scientific (BSX) PT Raised to $85 at Mizuho
• Cidara Therapeutics (CDTX) PT Raised to $25 at Needham
• Boston Scientific (BSX) PT Raised to $73 at Deutsche Bank